Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
NCCN Introduces New Vulvar Cancer Guideline
A new NCCN guideline for the management of vulvar cancer outlines the use of resection, radiation therapy, and chemotherapy based on disease site and stage, recognizing that only 2 randomized treatment trials have been completed.
Dr. Jeffrey Jones on NCCN Recommendations for Relapsed Patients With CLL
April 4th 2016Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses NCCN recommendations for treatment of relapsed patients with chronic lymphocytic leukemia (CLL).
TKIs Dominate NCCN Update in EGFR+ NSCLC
Testing for EGFR mutations should be routine in patients with non–small cell lung cancer. With the presence of an EGFR mutation TKIs are an appropriate treatment option across multiple lines of therapy, according to the latest update from the NCCN.
Dr. Horn on Incorporating T790M-Mutant NSCLC Agents Into NCCN Guidelines
April 2nd 2016Leora Horn, MD, MSc, clinical director, Thoracic Oncology Program, assistant vice chancellor for faculty development, Vanderbilt-Ingram Cancer Center, provides her thoughts on how agents targeted T790M-mutant NSCLC will be incorporated into NCCN guidelines.
Dr. Mohler on Overuse of ADT in Prostate Cancer and NCCN Guidelines
April 1st 2016James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses the use of androgen-deprivation therapy (ADT) for patients with prostate cancer and how the use is reflected in the NCCN guidelines.
NCCN's Evidence Blocks Make the Best of Imprecise Drug Data
The NCCN's Evidence Blocks need further data and refinement to overcome subtleties of distinction in drug performance, but they’re the best value system developed so far, NCCN officials reported at their 2016 Annual Conference.
Trial of Ovarian Chemotherapy Regimens Fails to Provide Clarity
Three different chemotherapy regimens, each combined with bevacizumab, failed to demonstrate an advantage for patients with advanced ovarian cancer or build on results of a landmark trial reported more than a decade ago.
Dr. Jean Hurteau on Diagnosing Ovarian Clear Cell Carcinoma
March 21st 2016Jean Hurteau, MD, professor, Division of Gynecologic Oncology at NorthShore University Health System, discusses the difficulties of diagnosing ovarian clear cell carcinoma. Hurteau says data for the diagnosis of the carcinoma is older, and is not relevant to contemporary diagnoses due to the fact that there were more mixed tumors previously than there are now.
Dr. Bobbie J. Rimel on Genetic Testing in Ovarian Cancer
March 21st 2016Bobbie J. Rimel, MD, assistant professor, Obstetrics and Gynecology, discusses discovering BRCA mutations early in ovarian cancer patients. Rimel says with the genetic information of knowing which patients harbor which genetic mutations, oncologists can offer their patients treatments such as PARP inhibitors, which are gene-specific.
Dr. Byrd on Ibrutinib's Impact on Treatment Landscape in CLL
March 21st 2016John Byrd, MD, director of the Division of Hematology, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, discusses the RESONATE 2 study, which looked at ibrutinib versus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia (CLL).
New Antiemetic Compares Favorably With Standard for Cisplatin Regimens
An investigational extended-release formulation of the antiemetic granisetron achieved a complete response more often than did ondansetron in cancer patients receiving highly emetogenic cisplatin-based chemotherapy.
Dr. Terri Febbraro on the Inverse Correlation Between Time on Chemotherapy and OS
March 21st 2016Terri Febbraro, MD, third year fellow, University of Chicago/NorthShore University Health System, discusses length of time receiving chemotherapy versus overall survival in patients with ovarian cancer. Febbraro says the study looked at three separate groups of patients with ovarian cancer based on the length of time they receieved chemotherapy, with the group being on chemotherapy the longest having the worst overall survival rates.
Dr. Martee Hensley on Trabectedin as a Treatment for Uterine Leiomyosarcoma
March 21st 2016Martee Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the introduction of trabectedin into the armamentarium for uterine leiomyosarcoma. Hensley says the FDA approval for the treatment requires patients to have had a prior anthracycline therapy, and the treatment will likely fall into the third- or fourth-line of treatment for the malignancy. She adds that trabectedin may fall into the fourth-line due to treatments such as pazopanib currently occupying the third-line.
Trabectedin Significantly Slows Progression in Uterine Leiomyosarcoma
Treatment with trabectedin significantly improved progression-free survival compared with dacarbazine in women with advanced uterine leiomyosarcoma, according to a subgroup analysis of the phase III SAR-3007 trial.
